Friday, February 25, 2011

Cutting-edge prostate cancer treatments could rescue Medivation, Exelixis

New weaponry is on the way to battle men’s No. 1 cancer killer, and perhaps rescue a couple Bay Area companies in the process.
Medivation Inc. and Exelixis Inc., hit hard by business or lab troubles over the past year, suddenly are handling potentially breakthrough prostate cancer treatments. Their studies are continuing, but data from early and mid-stage trials look promising.

No comments:

Post a Comment